The Pharmacy Times® Diabetes resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Lower-priced versions of Humalog Mix75/25 KwikPen and Humalog Junior KwikPen will be available in mid-April and will have 50% lower list prices compared with branded versions.
The treatment is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation, according to Novo Nordisk.
The immunogenicity and safety of hepatitis B surface antigen (HBsAg)/CpG 1018 was assessed in patients with diabetes aged 60 to 70 years.
Results of the DAPA-HF trial demonstrate the efficacy and safety of dapagliflozin in patients with heart failure.
Rates of some vaccinations are low in these patients, but pharmacists can play a key role in adherence.
According to Janet Woodcock, MD and director of FDA’s Center for Drug Evaluation and Research, the agency is focused on the drugs used by Americans continuing to meet “strict quality standards.”
A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.
The approval was based on a phase 3 EDITION JUNIOR trial evaluating children and adolescents, aged 6 to 17 years, living with type 1 diabetes.
Ocular conditions can lead to serious complications, and sometimes there are no early symptoms.
Metformin hydrochloride extended-release tablets are indicated to for improving glycemic control in patients with type 2 diabetes mellitus, as an adjunct to diet and exercise.
Clinical data has illustrated how digital interventions can have a substantial material benefit on glycemic control in users with diabetes, with 73 of 162 users in the study reducing their average blood glucose levels to under 140 mg/dL.
In honor of World Diabetes Day, AstraZeneca has launched the campaign Diabetes Can Break Your Heart, the national movement aimed to change the trajectory of heart failure in type 2 diabetes.